Immune booster plus Chemo-Radiation shows promise in Hard-to-Treat stomach cancer
NCT ID NCT07277439
First seen Jan 11, 2026 · Last updated May 10, 2026 · Updated 14 times
Summary
This study tests whether adding a drug called thymosin alpha 1 to standard chemo-radiation and immunotherapy can improve outcomes for people with stage III gastroesophageal junction cancer. About 48 adults who have not yet been treated will be randomly assigned to receive either the standard combination or the standard combination plus thymosin. The main goal is to see if the added drug leads to a complete disappearance of the tumor at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Nanjing Medical Unviersity
RECRUITINGNanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.